Pathogenesis and treatment of hepatic fibrosis: Is cirrhosis reversible?

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 11, Issue 2, 2011, Pages 179-183

  Fallowfield, Jonathan ^a   Hayes, Peter ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSINOGEN; ANTIFIBROTIC AGENT; ASPARTATE AMINOTRANSFERASE; CHEMOKINE RECEPTOR TYPE 5; COLLAGEN TYPE 1; CURCUMIN; DEAD BOX PROTEIN 5; HYALURONIC ACID; INTERLEUKIN 10; LEPTIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLATELET DERIVED GROWTH FACTOR; PROCOLLAGEN 3 N TERMINAL PEPTIDE; PROTEIN; REACTIVE OXYGEN METABOLITE; SILYMARIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSRESVERATROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

APOPTOSIS; ARTICLE; DISEASE COURSE; ECHOGRAPHY; ELASTOGRAPHY; EXTRACELLULAR MATRIX; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MYOFIBROBLAST; NUCLEAR MAGNETIC RESONANCE IMAGING; STELLATE CELL; STEM CELL TRANSPLANTATION; TRANSIENT ELASTOGRAPHY; CYTOLOGY; LIVER; LIVER REGENERATION; PATHOLOGY; REVIEW; RISK FACTOR;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER REGENERATION; RISK FACTORS;

EID: 79958121662     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.11-2-179     Document Type: Article

References (21)

1. The National Plan for Liver Services UK. A time to act: improving liver health and outcomes in liver disease. British Association for the Study of the Liver (BASL) and British Society of Gastroenterology (BSG) (Liver Section), 2009. www.bsg.org.uk/sections/liver-news/the-national-plan-for-liver-services- uk-2009.html
2. Iredale JP.Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-48.
3. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69. (Pubitemid 351615417)
4. Iredale JP, Benyon RC, Pickering J et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-49. (Pubitemid 28376157)
5. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004;40:860-7. (Pubitemid 38507370)
6. Issa R, Zhou X, Constandinou CM et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126:1795-808. (Pubitemid 38736345)
7. Duffield JS, Forbes SJ, Constandinou CM et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65. (Pubitemid 40385505)
8. Fallowfield JA,Mizuno M, Kendall TJ et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007;178:5288-95. (Pubitemid 46595314)
9. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599-607.
10. Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis - a histological classification of the severity of cirrhosis. J Hepatol 2006;44:111-7. (Pubitemid 41772524)
11. Poynard T, Ratziu V, Charlotte F et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9. (Pubitemid 32488789)
12. Hold GL, Untiveros P, Saunders KA, El- Omar EM. Role of host genetics in fibrosis. Fibrogenesis Tissue Repair 2009;2:6.
13. Fernández M, Semela D, Bruix J et al. Angiogenesis in liver disease. J Hepatol 2009;50:604-20.
14. Talwalkar JA. Antifibrotic therapies - emerging biomarkers as treatment end points. Nat Rev Gastroenterol Hepatol 2010;7:59-61.
15. Imbert-Bismut F, Ratziu V, Pieroni L et al; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
16. Plevris JN, Haydon GH, Simpson KJ et al. Serum hyaluronan - a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol 2000;12:1121-7.
17. Guha IN, Parkes J, Roderick P et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-60. (Pubitemid 351280713)
18. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009;30:557-76.
19. Fallowfield JA. Kendall TJ, Ireland JP. Reversal of fibrosis: no longer a pipe dream? Clin Liver Dis 2006;10:481-97
20. Rockey DC. Current and future antifibrotic therapies for chronic liver disease. Clin Liver Dis 2008;12:939-62.
21. Masterton GS, Hayes PC. Coffee and the liver: a potential treatment for liver disease? Eur J Gastroenterol Hepatol 2010;22:1277-83.